भारतीय भारोत्तोलन महासंघ
Indian Weightlifting Federation

IWLF

Affiliated to: International Weightlifting Federation, Asian Weightlifting Federation, Commonwealth Weightlifting Federation and Indian Olympic Association
Recognised by: Ministry of Youth Affairs & Sports, Govt. of India

Regd No.: S-4286/21.11.1960

Ref.: IWLF/NWLC-J&S/Kangra_H.P/2026-27 **Date: 17 November 2026**

All affiliated States, U.T. and
Departmental Boards of Indian Weightlifting Federation

Sub.: IWLF National Junior and Senior (Men & Women) Weightlifting Championships - 2026-27 at Arni University, Kangra, Himachal Pradesh from 5th to 13th February 2027.

Sir / Madam,

IWLF National Junior and Senior (Men & Women) Weightlifting Championships for the year 2026–27 will be held at Arni University, Kangra, Himachal Pradesh from 5th to 13th February 2027.

The following documents are enclosed herewith for necessary compliance:

1. Terms & Conditions for Participation
2. Entry Form (Excel format)
3. Whereabout Information/Registration Form shall be submitted in the attached Excel format. *Only the duly completed Excel-format entry form will be accepted.*
4. Specimen Dope Declaration Form to be submitted along with entries on 31st December 2026.
5. WADA Prohibited List of Substances for 2027
6. Provisional Timetable of the Competition

The deadline for submission of Entry Forms & the Whereabout Information is 31st December 2026. Athletes who fail to submit the Whereabout Information by the stipulated deadline shall not be permitted to participate.

Boarding & Lodging will be provided to the participating athletes and team officials by the Organizing Committee at Kangra, Himachal Pradesh during the competition days. The provisional time table is subject to change after verification of final entries on 20th January 2027.

Indian Weightlifting Federation NOIDA

ELEIKO
Nelco Do....Dare....Win !!
SHIV-NARESH Official Sportwear Partner

C-2/18, Sector-31, Noida, Uttar Pradesh-201301 (India)
Ph. No.: 0120-4541605
Email: weightlifting@weightliftingindia.in Website: www.iwlf.in

All affiliated units are advised to read the enclosed documents carefully and ensure strict compliance with the prescribed terms and conditions.

Yours Sincerely,

17/1/2026

Indian Weightlifting Federation
NOIDA

Ashwani Kumar
Chief Executive Officer

Encl. as above.

TERMS AND CONDITIONS FOR PARTICIPATION IN THE IWLF NATIONAL JUNIOR (MEN & WOMEN) AND SENIOR (MEN & WOMEN) WEIGHTLIFTING CHAMPIONSHIPS - 2026-27 – ARNI UNIVERSITY, KANGRA, HIMACHAL PRADESH W.E.F. 5th TO 13th February 2027

1	Dates of Competition		5th to 13th February 2027
2	Boarding & Lodging		**Boarding and lodging will be provided by the Organizers to the athletes and team officials on competition days.**
3	Verification of Final entries meeting (Online)		The Verification form will be distributed on 10th January 2027. The verification form in PDF, to be checked by participating States and Departmental Boards, cutting with blue pen, signatures and seal is allowed and accepted on the verification forms. All stakeholders to return the verification forms by email by 12th January 2027 (2 p.m.)
4	Publication of Start Book with Time Table		20th January 2027
5	Technical Officials Meeting		04th February 2027 at 5:00 p.m.
6	Last date of receipt of entries (in excel file soft copy only)		31st December 2026 (23:59 Hrs.)
7	**Weight Categories**		
	Junior & Senior (Men)		60 kg, 65 kg, 70 kg, 75 kg, 85 kg, 95 kg, 110 kg, and +110 kg
	Junior & Senior (Women)		49 kg, 53 kg, 57 kg, 61 kg, 69 kg, 77 kg, 86 kg, and +86 Kg
8	**Athlete's Age for participation**		
	Senior (Men & Women)		Born on or before 31-12-2011(15 years)
	Junior (Men & Women)		Born between 1-1-2006 to 31-12-2011 (15 to 20 years)
9	**Minimum qualifying weights / standards**		

Junior (Men)

WEIGHT CATEGORIES-	60	65	70	75	85	95	110	+110
SNATCH	88	102	105	108	110	111	112	112
CLEAN AND JERK	113	126	125	131	140	141	140	150
TOTAL	**201**	**228**	**230**	**239**	**250**	**252**	**252**	**262**

Junior (Women)


WEIGHT CATEGORIES-	49	53	57	61	69	77	86	+86
SNATCH	60	60	63	65	68	70	61	59
CLEAN AND JERK	70	72	77	82	83	87	83	76
TOTAL	**130**	**132**	**140**	**147**	**151**	**157**	**144**	**135**

Indian Weightlifting Federation NOIDA

	Senior (Men)								
	WEIGHT CATEGORIES-	**60**	**65**	**70**	**75**	**85**	**95**	**110**	**+110**
	SNATCH	101	108	113	115	125	128	131	140
	CLEAN AND JERK	123	136	142	148	154	160	160	162
	TOTAL	**224**	**244**	**255**	**263**	**279**	**288**	**291**	**302**
	Senior (Women)								
	WEIGHT CATEGORIES-	**49**	**53**	**57**	**61**	**69**	**77**	**86**	**+86**
	SNATCH	63	68	73	70	75	80	81	79
	CLEAN AND JERK	85	88	96	90	93	98	101	102
	TOTAL	**148**	**156**	**169**	**160**	**168**	**178**	**183**	**181**

Please note that 20 kg Rule will be applicable above the minimum qualifying weights / standard in each body weight category.

10	**Maximum number of entries from a participating State / Department**	
	Junior Men	8 athletes + 2 reserves (not more than 2 in a weight category)
	Junior Women	8 athletes + 2 reserves (not more than 2 in a weight category)
	Senior Men	8 athletes + 2 reserves (not more than 2 in a weight category)
	Senior Women	8 athletes + 2 reserves (not more than 2 in a weight category)
	RESERVE ATHLETES TO BE DELETED IN THE FINAL VERIFICATION OF ENTRIES ON 12-01-2027	
	Wild Card entries	Those States who do not qualify with minimum standards can enter with 1 wild card from the State, with a maximum of 4 wild cards - 1, in Junior Men, 1 in Junior Women, 1 in Senior Men and 1 in Senior Women
	Venue of the Championships	**Arni University, Kangra, Himachal Pradesh**
	Whereabout Information deadline	**31st December 2026**
11	ID Cards	Possession of ONLINE ID cards are mandatory to participate
12	Dope Test	The dope tests will be carried out by National Anti-Doping Agency, New Delhi as per norms
13	WADA Prohibited Substances	List of WADA Prohibited Substances for the year 2027 is attached.
14	Undertaking (Dope Declaration Form)	The Doping Declaration Form must be duly completed in all respects, to be submitted by participating states and Departments **on or before 31st December 2026 in hard copies by Courier and in pdf scanned file by email.** The **signature and official stamp/seal of the concerned State Association/Departmental Board are mandatory to be affixed on the form along with ADEL certificate.**



15	Weather Climate		The Average temperatures will range from 17°C to 24°C during the day and 7°C and 12°C during the night.
16	How to reach Kangra, Himachal Pradesh		By Air: Nearest Airport is Kangra Airport, also known as Gaggal Airport or Dharamshala Airport. (10-15 Km from Kangra Town) By Train: Pathankot Railway Station (85–90 km from Kangra) By Road: Kangra is approximately 450–470 km from New Delhi.
17	Entry Forms		Attached separately - both soft copy excel file and hard copy (duly stamped and signed) will be entertained through official email id of State Association and Departmental Boards
18	Name of Coach in entry forms		The word SELF / SELF TRAINING is prohibited. Coaches must be registered with a valid NSRS ID on Khelo India portal.
19	Education on banned substances and WADA prohibited List published		It is solely the responsibility of Secretary of State Association / Coach to educate athletes about the WADA / NADA code and list of prohibited substances published from time to time
20	Re-admission in weightlifting activities after expiry of BAN period		Athletes completed suspension period are only eligible to participate if they have provided the Whereabout Information in prescribe Excel Sheet closed on 31-12-2026
21	Medals		Medals will be distributed for TOTAL event.
22	Diploma		**Diplomas will be issued in online digital format through DIGILOCKER for** the first 3 places to athletes, after receipt of dope test results from National Anti-Doping Agency, New Delhi.
23	Participation Certificate		**Participation certificates will be issued online through DIGILOCKER.** Only those athletes will be issued Participation Certificates who will pass at least 1 lift in Snatch and 1 lift Clean & Jerk event. Those athletes who gets eliminated in Snatch will not be allowed to compete in Clean & Jerk event and will not be issued any Participation Certificate by the Organizers.
24	Inter-State Transfers		Inter-State transfers shall be permitted only if the athlete has resided in the participating State at least six (6) months immediately preceding the commencement of the competition, supported by

Indian Weightlifting Federation NOIDA

			valid proof of address, and possesses an NOC from the State Association last represented. However, if the athlete has not represented the previously registered State for a period of two (2) years or more, the NOC requirement shall be waived, subject to submission of valid proof of address. Possession of a valid identity card, as prescribed by the Federation, shall be mandatory for participation in the competition.
25	Reasons for rejection of entries by the Federation		**Within the stipulated timelines as per circular with** • Missing ADEL Certificate (2025 or later). • Non-submission of Whereabouts Information. • Pending Doping Penalties and Other Outstanding Dues to States/Departments. • Disciplinary Issues. • Missing Athlete ID Cards numbers.
26	Additional Registration for Athletes, Coaches and support staff		Registration of Khelo India portal is mandatory for all athletes, Coaches and Support Staff. It is mandatory to write KID no. of the Undertaking Form by participating athletes and Coaches. Secretary of State Association/Departments must comply.
27	Official Email id for sending entry forms		nwlc25onw@gmail.com

Indian Weightlifting Federation NOIDA

[ASHWANI KUMAR]
CHIEF EXECUTIVE OFFICER
INDIAN WEIGHTLIFTING FEDERATION

DATE: 17-11-2026
PLACE - NOIDA

UNDERTAKING
DOPE DECLARATION FORM

I, _____ representing _____ participating in _____ kg weight category in **IWLF National Junior (Men & Women) and Senior (Men & Women) Weightlifting Championships-2026-27 held at Kangra, Himachal Pradesh from 5th to 13th February 2027** hereby declare and certify on oath that **I am aware of names of banned drugs and prohibited list of banned substances under LATEST WADA / NADA code and state with full responsibility that I have not consumed any banned substance as per latest WADA / NADA rules and regulations and that I am absolutely free from banned drugs.**

In case of my positive dope test at the above event I shall solely be responsible for the same and shall be liable for all consequences arising out of my positive dope test as provided in the Anti-Doping Rules / Policy of Indian Weightlifting Federation and National Anti-Doping Agency.

I further undertake that it is my personal duty to ensure that no Prohibited Substance enters my body. I am responsible for any Prohibited Substance or its Metabolites or Markers found to be present in my urine or blood sample. Accordingly, it is not necessary that intent, fault, negligence or knowing Use on my part be demonstrated in order to establish an anti-doping violation.

I certify that I understand the contents of this undertaking which has been explained to me by my Coach / Manager / Secretary of my State Association in the language known to me.

Name (in CAPITAL letters)	
Father's Name	
Address	
IWLF ID Card No. & Khelo India (NSRS) ID No.	
Mobile no.	
Email id	
Name of Bank	
Bank Address	
Account No.	
RTGS / IFSC Code ***(Enclose copy of cancelled cheque / pass book front page)***	

Aadhar Card no.
(Enclose copy)

Signature of Athlete:. . . . .
State / Unit: .....

Indian Weightlifting Federation NOIDA

Certified by COACH:-

I. _____, coach of above athlete agree to abide by rules and regulations of Anti-Doping Policy of Indian Weightlifting Federation / National Anti-Doping Agency and is aware of the consequences of use of banned drug(s) by my above trainee. I support and abide by the sanctions imposed on me by Indian Weightlifting Federation / National Anti-Doping Agency in case of above athlete being testing positive.

Countersigned: .....

Name of Coach: ..... **Mobile no. .....**

Aadhar Card No. ..... (Enclose copy)

Verified & Certified by STATE ASSOCIATION:-

I hereby certify that information provided in this Undertaking / Dope Declaration form is true and correct. I will be responsible for any discrepancy found in this form and actions thereof. I undertake to pay the administrative dope penalty charges of Rs. 50,000/- per positive dope test case as the State / Unit liability within 30 days and accept the suspension of the State Association / forfeiture of participation in any future Championship(s) / competitions as an affiliate Unit / as individual lifter till such time this financial outstanding is cleared.

.....
[Secretary]

State / Unit .....

Dated: ..... **With seal**

Enclose copy of Aadhar card of Athlete & Coach,
ADEL certificate of Athlete & Coach and
Copy of cancelled cheque / front page of passbook of the Athlete.

Indian Weightlifting Federation
NOIDA

TIME TABLE (PROVISIONAL)

IWLF NATIONAL JUNIOR AND SENIOR (MEN & WOMEN) WEIGHTLIFTING CHAMPIONSHIPS

AT ARNI UNIVERSITY, KANGRA, HIMACHAL PRADESH

FROM 5th to 13th February 2027

Day	Date	Program / Event
	31/12/2026	Last date of submission of Whereabout Information
	01/01/2027	Final entry receipt
	12/01/2027	Submission of Verification Forms upto 2:00 p.m.
	20/01/2027	Publication of Start Book
	04/02/2027	Technical Officials Meeting (5:00 p.m.)
	Junior & Senior (Men & Women) Championships	
1	05/02/2027	49 Kg Women (A, B & C) , 60 Kg Men (Group A, B & C)
2	06/02/2027	65 Kg Men (Group A, B & C), 53 Kg Women (A, B & C)
3	07/02/2027	70 Kg Men (A, B, C & D), 57 Kg Women (Group C)
4	08/02/2027	57 Kg Women (Group A & B), 75 KG Men (Group B, C & D)
5	09/02/2027	75 KG Men (Group A), 61 Kg Women (Group A, B & C), 85 Kg Men (Group C)
6	10/02/2027	85 Kg Men (Group A & B), 69 Kg Women (A, B & C)
7	11/02/2027	95 Kg Men (Group A, B & C), 77 Kg Women (Group A & B)
8	12/02/2027	110 Kg Men (Group A, B & C), 86 Kg Women (A & B)
9	13/02/2027	+110 Kg Men (A & B), + 86 Kg Women (A & B)

Note:
* **Above time table is based on entries received during last edition of National Championships, Modinagar**
* **Final competition time table will be published on 20-01-2027**
* **Body weight will start 3 hours prior to the start of the competition**
* **Boarding and lodging facilities shall be provided to participating teams for the period one day prior to the commencement of the competition and continuing through the day of their respective competition, in accordance with the prescribed arrangements and applicable guidelines.**

Indian Weightlifting Federation
NOIDA

NATIONAL WEIGHTLIFTING CHAMPIONSHIPS 2026-27

Athlete Entry & Dope Test Whereabouts Information Form (Junior and Senior - Kangra, Himachal Pradesh - 3 to 13 Feb 27)

S.No.	Name of Athlete	Participating In	Gender	Aadhaar Card No	Mobile No	Email ID	IWLF ID Card No	NSRS ID (KID)	District	State / U.T. / Department	Overnight Accommodation Address with Pin Code	Training Slot (Dope Test)	Gym Address with Pin Code (Training)	Days when you are training	Training Time Slot	ADAMS ID	Name of Coach	Coach Mobile No & Email ID	Dope Positive Case in Past?	Suspension Expiry (if	Undertaking Accepted?
1		Junior - Kangra- 3-13 February 2027																			
2		Senior - Kangra- 3-13 February 2027																			
3		Junior & Senior- Kangra- 3-13 February 2027																			
4																					
5																					
6																					
7																					
8																					
9																					
10																					
11																					
12																					
13																					
14																					
15																					
16																					
17																					
18																					
19																					
20																					
21																					

Seal

_____**Signature**

Name :
Designation:
Name of affiliated Unit:

ENTRY FORM FOR PARTICIPATION OF ATHLETES AND TEAM OFFCIALS DURING IWLF NATIONAL JUNIOR (MEM & WOMEN) AND SENIOR (MEN & WOMEN) WEIGHTLIFTING CHAMPIONSHIPS - 2026-27 TO BE HELD AT ARNI UNIVERSITY, KANGRA, HIMACHAL PRADESH FROM 5 - 13 FEBRUARY 2027

S.No.	Athlete First Name	Athlete Last Name	Father's Name	State/U.T. /Department	Gender (M/W)	DOB	Weight Category (Don't write kg)	Entry Total (Don't write kg)	Section (J / S)	ID Card no.	NSRS ID	Name of Coach	Dope positive in past (Yes / No)	Suspended upto (Mention date or N.A.)
1														
2														
3														
4														
5														

S.No.	Name of Officials	Desgination	Mobile no.	State/U.T. /Department	Gender (M/W)	Email id
1						
2						
3						
4						
5						

Seal _____ **Signature**

Name :
Designation:
Name of affiliated Unit:

wada



WORLD ANTI-DOPING CODE

INTERNATIONAL STANDARD

PROHIBITED LIST

2027

This List shall come into effect on 1 January 2027.

TABLE OF CONTENTS

Please note that the list of examples of medical conditions below is not inclusive.

SUBSTANCES & METHODS PROHIBITED AT ALL TIMES

S0 **Non-approved substances** 4

S1 **Anabolic agents** 5
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism.

S2 **Peptide hormones, growth factors, related substances, and mimetics** 7
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency.

S3 **Beta-2 agonists** 9
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders.

S4 **Hormone and metabolic modulators** 10
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome.

S5 **Diuretics and masking agents** 12
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

M1 – M2 – M3 **Prohibited Methods** 13

SUBSTANCES & METHODS PROHIBITED IN-COMPETITION

S6 **Stimulants** 15
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms.

S7 **Narcotics** 17
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.

S8 **Cannabinoids** 18

S9 **Glucocorticoids** 19
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease.

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS

P1 **Beta-blockers** 20
Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension.

INDEX 21

THE 2027 PROHIBITED LIST WORLD ANTI-DOPING CODE

VALID 1 JANUARY 2027

Introduction

The *Prohibited List* is a mandatory *International Standard* as part of the World Anti-Doping Program.

The *List* is updated annually following an extensive consultation process facilitated by *WADA*. The effective date of the *List* is 01 January 2027.

The official text of the *Prohibited List* shall be maintained by *WADA* and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.

Below are some terms used in this *List* of *Prohibited Substances* and *Prohibited Methods*.

Prohibited In-Competition

Subject to a different period having been approved by *WADA* for a given sport, the *In-Competition* period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a *Competition* in which the *Athlete* is scheduled to participate until the end of the *Competition* and the *Sample* collection process.

Prohibited at all times

This means that the substance or method is prohibited *In-* and *Out-of-Competition* as defined in the *Code*.

Specified and **non-*Specified***

As per Article 4.2.2 of the *World Anti-Doping Code*, "for purposes of the application of Article 10, all *Prohibited Substances* shall be *Specified Substances* except as identified on the *Prohibited List*. No *Prohibited Method* shall be a *Specified Method* unless it is specifically identified as a *Specified Method* on the *Prohibited List*". As further stated in the article, "the *Specified Substances* and *Methods* identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an *Athlete* for a purpose other than the enhancement of sport performance."

Substances of Abuse

Pursuant to Article 4.2.3 of the Code, *Substances of Abuse* are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated *Substances of Abuse*: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/"ecstasy"), tetrahydrocannabinol (THC) or their metabolites, if their presence is consistent with the *Use* of a *Substance of Abuse*.

Published by:
World Anti-Doping Agency
Place Victoria, 800, rue du
Square-Victoria, bureau 1700
Montréal (Québec)
H3C 0B4 Canada

URL: www.wada-ama.org
Tel: +1 514 904 9232
Fax: +1 514 904 8650
E-mail: code@wada-ama.org

S0 NON-APPROVED SUBSTANCES

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*.

Any pharmacological substance which is not addressed by any of the subsequent sections of the *List* and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, peptides, substances approved only for veterinary use) is prohibited at all times.

This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers [e.g. S-107, S48168 (ARM210)] and troponin activators (e.g. reldesemtiv and tirasemtiv).

S1 ANABOLIC AGENTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-*Specified Substances*.

Anabolic agents are prohibited.

S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS)

When administered exogenously, including but not limited to:

- 1-Androstenediol (5α-androst-1-ene-3ß, 17ß-diol)
- 1-Androstenedione (5α-androst-1-ene-3, 17-dione)
- 1-Androsterone (3α-hydroxy-5α-androst-1-ene-17-one)
- 1-Epiandrosterone (3ß-hydroxy-5α-androst-1-ene-17-one)
- 1-Testosterone (17ß-hydroxy-5α-androst-1-en-3-one)
- 4-Androstenediol (androst-4-ene-3ß, 17ß-diol)
- 4-Hydroxytestosterone (4,17ß-dihydroxyandrost-4-en-3-one)
- 5-Androstenedione (androst-5-ene-3,17-dione)
- 7α-Hydroxy-DHEA
- 7ß-Hydroxy-DHEA
- 7-Keto-DHEA
- 11ß-Methyl-19-nortestosterone
- 17α-Methylepithiostanol (epistane)
- 19-Norandrostenediol (estr-4-ene-3,17-diol)
- 19-Norandrostenedione (estr-4-ene-3,17-dione)
- Androst-4-ene-3,11,17- trione (11-ketoandrostenedione, adrenosterone)
- Androstanolone (5α-dihydrotestosterone, 17ß-hydroxy-5α-androstan-3-one)
- Androstenediol (androst-5-ene-3ß,17ß-diol)
- Androstenedione (androst-4-ene-3,17-dione)
- Bolasterone
- Boldenone
- Boldione (androsta-1,4-diene-3,17-dione)
- Calusterone
- Clostebol
- Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol)
- Dehydrochlormethyltestosterone (4-chloro-17ß-hydroxy-17α-methylandrosta-1,4-dien-3-one)
- Desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17ß-ol and 17α-methyl-5α-androst-3-en-17ß-ol)
- Dimethandrolone (7α,11ß-Dimethyl-19-nortestosterone)
- Drostanolone
- Epiandrosterone (3ß-hydroxy-5α-androstan-17-one)
- Epi-dihydrotestosterone (17ß-hydroxy-5ß-androstan-3-one)
- Epitestosterone
- Ethylestrenol (19-norpregna-4-en-17α-ol)
- Fluoxymesterone
- Formebolone
- Furazabol (17α-methyl [1,2,5] oxadiazolo[3',4':2,3]-5α-androstan-17ß-ol)

S1 ANABOLIC AGENTS (continued)

S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued)

- Gestrinone
- Mestanolone
- Mesterolone
- Metandienone (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-one)
- Metenolone
- Methandriol
- Methasterone (17ß-hydroxy-2α,17α-dimethyl-5α-androstan-3-one)
- Methyl-1-testosterone (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-one)
- Methylclostebol
- Methyldienolone (17ß-hydroxy-17α-methylestra-4,9-dien-3-one)
- Methylnortestosterone (17ß-hydroxy-17α-methylestr-4-en-3-one)
- Methyltestosterone
- Metribolone (methyltrienolone, 17ß-hydroxy-17α-methylestra-4,9,11-trien-3-one)
- Mibolerone
- Nandrolone (19-nortestosterone)
- Norboletone
- Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one)
- Norethandrolone
- Oxabolone
- Oxandrolone
- Oxymesterone
- Oxymetholone
- Prasterone (dehydroepiandrosterone, DHEA, 3ß-hydroxyandrost-5-en-17-one)
- Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane)
- Quinbolone
- Stanozolol
- Stenbolone
- Testosterone
- Tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one)
- Tibolone
- Trenbolone (17ß-hydroxyestr-4,9,11-trien-3-one)
- Trestolone (7α-Methyl-19-nortestosterone, MENT)

and other substances with a similar chemical structure or similar biological effect(s) including their esters.

S1.2. OTHER ANABOLIC AGENTS

Including, but not limited to:

Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol.

S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are non-*Specified Substances*.

The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited.

S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS

Including, but not limited to:

S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide, pegmolesatide).

S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.

S2.1.3 GATA inhibitors, e.g. K-11706.

S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept.

S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO).

S2 PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES, AND MIMETICS (continued)

S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS

S2.2.1 Testosterone-stimulating peptides in males including, but not limited to:

- chorionic gonadotrophin (CG)
- luteinizing hormone (LH)
- gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin)
- kisspeptin and its agonist analogues

S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide

S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to:

- growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon
- growth hormone fragments, e.g. AOD-9604 and hGH 176-191

S2.2.4 Growth hormone releasing factors, including, but not limited to:

- growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
- growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]
- GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]

S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS

Including, but not limited to:

- Fibroblast growth factors (FGFs)
- Hepatocyte growth factor (HGF)
- Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues
- Mechano growth factors (MGFs)
- Platelet-derived growth factor (PDGF)
- Thymosin-ß4 and its derivatives e.g. TB-500
- Vascular endothelial growth factor (VEGF)

and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching.

S3 BETA-2 AGONISTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*.

All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.

Including, but not limited to:

- Arformoterol
- Fenoterol
- Formoterol
- Higenamine
- Indacaterol
- Levosalbutamol
- Olodaterol
- Procaterol
- Reproterol
- Salbutamol
- Salmeterol
- Terbutaline
- Tretoquinol (trimetoquinol)
- Tulobuterol
- Vilanterol

EXCEPTIONS

- Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 600 micrograms over 8 hours starting from any dose
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours in divided doses not to exceed 36 micrograms over 12 hours starting from any dose
- Inhaled salmeterol: maximum 200 micrograms over 24 hours in divided doses not to exceed 100 micrograms over 8 hours starting from any dose
- Inhaled vilanterol: maximum 25 micrograms over 24 hours

NOTE

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above.

S4 HORMONE AND METABOLIC MODULATORS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

Prohibited substances in classes S4.1 and S4.2 are *Specified Substances*.
Those in classes S4.3 and S4.4 are non-*Specified Substances*.

The following hormone and metabolic modulators are prohibited.

S4.1. AROMATASE INHIBITORS

Including, but not limited to:

- 2-Androstenol (5α-androst-2-en-17-ol)
- 2-Androstenone (5α-androst-2-en-17-one)
- 2-Phenylbenzo[h]chromen-4-one (α-naphthoflavone; 7,8-benzoflavone)
- 3-Androstenol (5α-androst-3-en-17-ol)
- 3-Androstenone (5α-androst-3-en-17-one)
- 4-Androstene-3,6,17 trione (6-oxo)
- Aminoglutethimide
- Anastrozole
- Androsta-1,4,6-triene-3,17-dione (androstatrienedione)
- Androsta-3,5-diene-7,17-dione (arimistane)
- Exemestane
- Formestane
- Letrozole
- Testolactone

S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) OR DEGRADERS (SERDS)]

Including, but not limited to:

- Bazedoxifene
- Clomifene
- Cyclofenil
- Elacestrant
- Fulvestrant
- Imlunestrant
- Ospemifene
- Raloxifene
- Tamoxifen
- Toremifene

S4 HORMONE AND METABOLIC MODULATORS (continued)

S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION

Including, but not limited to:

- Activin A-neutralizing antibodies
- Activin receptor IIB competitors such as:
  - Decoy activin receptors (e.g. ACE-031)
- Anti-activin receptor IIB antibodies (e.g. bimagrumab)
- Myostatin inhibitors such as:
  - Agents reducing or ablating myostatin expression
  - Myostatin-binding proteins (e.g. follistatin, myostatin propeptide)
  - Myostatin- or precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab)

S4.4. METABOLIC MODULATORS

S4.4.1

- Activators of the AMP-activated protein kinase (AMPK), e.g. 5-*N*,6-*N*-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine (BAM15), AICAR, mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)
- Peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516), seladelpar
- Rev-erbα agonists, e.g. SR9009, SR9011
- SLU-PP-332, SLU-PP-915 and related substances

S4.4.2 Insulins and insulin-mimetics, e.g. S519, S597

S4.4.3 Meldonium

S4.4.4 Trimetazidine

S5 DIURETICS AND MASKING AGENTS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited substances in this class are *Specified Substances*.

All diuretics and masking agents, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

Including, but not limited to:

- Diuretics such as:

  Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; eplerenone; etacrynic acid; finerenone; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; xipamide
- Vaptans, e.g. conivaptan, mozavaptan, tolvaptan
- Plasma expanders by intravenous administration such as:

  Albumin, dextran, hydroxyethyl starch, mannitol
- Desmopressin
- Probenecid

and other substances with a similar chemical structure or similar biological effect(s).

EXCEPTIONS

- Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide)
- Local administration of felypressin in dental anaesthesia

NOTE

The detection in an *Athlete's Sample* at all times or *In-Competition*, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered as an *Adverse Analytical Finding (AAF)* unless the *Athlete* has an approved *Therapeutic Use Exemption (TUE)* for that substance in addition to the one granted for the diuretic or masking agent.

PROHIBITED METHODS

PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)

All prohibited methods in this class are non-*Specified* except methods in M2.2. which are *Specified Methods*.

M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS

The following are prohibited:

M1.1. The *Administration* or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.

The withdrawal of blood or blood components (including by apheresis), unless performed for 1) analytical purposes including medical tests or *Doping Control*, or for 2) donation purposes in a collection center accredited by the relevant regulatory authority of the country in which it operates.

M1.2. Artificially enhancing the uptake, transport or delivery of oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation.

M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M1.4. The use of re-breathing systems or equipment to deliver carbon monoxide, unless performed as a diagnostic procedure under the supervision of a medical or scientific professional.

M2. CHEMICAL AND PHYSICAL MANIPULATION

The following are prohibited:

M2.1. *Tampering*, or *Attempting to Tamper*, to alter the integrity and validity of *Samples* collected during *Doping Control.*

Including, but not limited to:

Sample substitution and/or adulteration, e.g. addition of proteases to *Sample*.

M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.

PROHIBITED METHODS
(continued)

M3. GENE AND CELL DOPING

The following, with the potential to enhance sport performance, are prohibited:

M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies.

M3.2. The use of normal or genetically modified cells or cell components (e.g. nuclei and organelles such as mitochondria and ribosomes).

S6 STIMULANTS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances* except those in S6.A, which are non-*Specified Substances*.

Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / "ecstasy")

All stimulants, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

Stimulants include:

S6.A: NON-SPECIFIED STIMULANTS

- Adrafinil
- Amfepramone
- Amfetamine
- Amfetaminil
- Amiphenazole
- Benfluorex
- Benzylpiperazine
- Bromantan
- Clobenzorex
- Cocaine
- Cropropamide
- Crotetamide
- Fencamine
- Fenetylline
- Fenfluramine
- Fenproporex
- Fladrafinil (2-[Bis(4-fluorophenyl) methylsulfinyl]-N-hydroxyacetamide)
- Flmodafinil (2-[Bis(4-fluorophenyl) methylsulfinyl]acetamide)
- Fonturacetam [4-phenylpiracetam (carphedon)]
- Furfenorex
- Hydrafinil (fluorenol)
- Lisdexamfetamine
- Mefenorex
- Mephentermine
- Mesocarb
- Metamfetamine(*d*-)
- p-methylamfetamine
- Modafinil
- Norfenfluramine
- Phendimetrazine
- Phentermine
- Prenylamine
- Prolintane

A stimulant not expressly listed in this section is a *Specified Substance*.

S6 STIMULANTS (continued)

S6.B: SPECIFIED STIMULANTS

Including, but not limited to:

- 2-phenylpropan-1-amine (ß-methylphenylethyl-amine, BMPEA)
- 3-Methylhexan-2-amine (1,2-dimethylpentylamine)
- 4-Fluoromethylphenidate
- 4-Methylhexan-2-amine (1,3-dimethylamylamine, 1,3 DMAA, methylhexaneamine)
- 4-Methylpentan-2-amine (1,3-dimethylbutylamine)
- 5-Methylhexan-2-amine (1,4-dimethylamylamine, 1,4-dimethylpentylamine, 1,4-DMAA)
- Benzfetamine
- Cathine**
- Cathinone and its analogues, e.g. mephedrone, methedrone, and α -pyrrolidinovalerophenone
- Dimetamfetamine (dimethylamphetamine)
- Ephedrine***
- Epinephrine**** (adrenaline)
- Etamivan
- Ethylphenidate
- Etilamfetamine
- Etilefrine
- Famprofazone
- Fenbutrazate
- Fencamfamin
- Heptaminol
- Hydroxyamfetamine (parahydroxyamphetamine)
- Isometheptene
- Levmetamfetamine
- Meclofenoxate
- Methylenedioxymethamphetamine
- Methylephedrine***
- Methylnaphthidate [(±)-methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate]
- Methylphenidate
- Midodrine
- Nikethamide
- Norfenefrine
- Octodrine (1,5-dimethylhexylamine)
- Octopamine
- Oxilofrine (methylsynephrine)
- Pemoline
- Pentetrazol
- Phenethylamine and its derivatives
- Phenmetrazine
- Phenpromethamine
- Propylhexedrine
- Pseudoephedrine*****
- Selegiline
- Sibutramine
- Solriamfetol
- Strychnine
- Tenamfetamine (methylenedioxyamphetamine)
- Tesofensine
- Tuaminoheptane

and other substances with a similar chemical structure or similar biological effect(s).

ⓘ EXCEPTIONS

- Clonidine, guanfacine
- Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2027 Monitoring Program*

* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2027 Monitoring Program and are not considered *Prohibited Substances*.

** Cathine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre.

S7 NARCOTICS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

Substance of Abuse in this section: diamorphine (heroin)

The following narcotics, including all optical isomers, e.g. *d*- and *l*- where relevant, are prohibited.

- Buprenorphine
- Dextromoramide
- Diamorphine (heroin)
- Fentanyl and its derivatives
- Hydromorphone
- Methadone
- Morphine
- Nicomorphine
- Oxycodone
- Oxymorphone
- Pentazocine
- Pethidine
- Tramadol

S8 CANNABINOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

Substance of Abuse in this section: tetrahydrocannabinol (THC)

Tetrahydrocannabinols (THC), as well as semi-synthetic and synthetic cannabinoids that mimic the effects of Δ^9-THC, are prohibited, e.g.

- Δ^9-THC as found in cannabis (hashish, marijuana)
- Δ^8-THC and Δ^{10}-THC
- Hexahydrocannabinols (HHC)
- AB-FUBINACA, 5F-ADB

⚠ NOTE

- Cannabidiol (CBD) is not prohibited.

S9 GLUCOCORTICOIDS

PROHIBITED IN-COMPETITION

All prohibited substances in this class are *Specified Substances*.

All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route.

Including, but not limited to:

- Beclometasone
- Betamethasone
- Budesonide
- Ciclesonide
- Cortisone
- Deflazacort
- Dexamethasone
- Flunisolide
- Fluocortolone
- Fluticasone
- Hydrocortisone
- Methylprednisolone
- Mometasone
- Prednisolone
- Prednisone
- Triamcinolone acetonide

⚠ NOTE

- Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic, perianal and vaginal) are not prohibited when used within the manufacturer's licensed doses and therapeutic indications.

P1 BETA-BLOCKERS

PROHIBITED IN PARTICULAR SPORTS

All prohibited substances in this class are *Specified Substances*.

Beta-blockers are prohibited *In-Competition* only, in the following sports, and also prohibited *Out-of-Competition* where indicated (*).

- Archery (WA)*
- Automobile (FIA)
- Billiards (WCBS)
- Darts (WDF)
- Golf (IGF)
- Mini-Golf (WMF)
- Shooting (ISSF, IPC)*
- Underwater sports (CMAS)* in all subdisciplines of freediving, spearfishing and target shooting

*Also prohibited *Out-of-Competition*

Including, but not limited to:

- Acebutolol
- Alprenolol
- Atenolol
- Betaxolol
- Bisoprolol
- Bunolol
- Carteolol
- Carvedilol
- Celiprolol
- Esmolol
- Labetalol
- Metipranolol
- Metoprolol
- Nadolol
- Nebivolol
- Oxprenolol
- Pindolol
- Propranolol
- Sotalol
- Timolol

INDEX

(±)-Methyl-2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate, 16

1-Androstenediol, 5

1-Androstenedione, 5

1-Androsterone, 5

1-Epiandrosterone, 5

1-Testosterone, 5

1,2-Dimethylpentylamine, 16

[1,2]Oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol), 5

1,3-Dimethylamylamine (1,3 DMAA), 16

1,3-Dimethylbutylamine, 16

1,4-Dimethylamylamine (1,4-DMAA), 16

1,4-Dimethylpentylamine, 16

1,5- Dimethyl-hexylamine, 16

2-Androstenol, 10

2-Androstenone, 10

2-[Bis(4-fluorophenyl)methylsulfinyl] acetamide, 15

2-[Bis(4-fluorophenyl)methylsulfinyl]-N-hydroxyacetamide, 15

2-Phenylbenzo[h]chromen-4-one, 10

2-Phenylpropan-1-amine, 16

2,4-Dinitrophenol (DNP), 4

3α-Hydroxy-5α-androst-1-ene-17-one, 5

3ß-Hydroxy-5α-androst-1-ene-17-one, 5

3ß-Hydroxy-5α-androstan-17-one, 5

3ß-Hydroxyandrost-5-en-17-one, 6

3-Androstenol, 10

3-Androstenone, 10

3-Methylhexan-2-amine, 16

4-Androstene-3,6,17 trione, 10

4-Androstenediol, 5

4-Chloro-17ß-hydroxy-17α-methylandrosta-1,4-dien-3-one, 5

4-Chloro-17ß-ol-estr-4-en-3-one, 6

4-Fluoromethylphenidate, 16

4-Hydroxytestosterone, 5

4-Methylhexan-2-amine, 16

4-Methylpentan-2-amine, 16

4-Phenylpiracetam, 15

4,17ß-Dihydroxyandrost-4-en-3-one, 5

5α-Androst-1-ene-3, 17-dione, 5

5α-Androst-1-ene-3ß, 17ß-diol, 5

5α-Androst-2-en-17-ol, 10

5α-Androst-2-en-17-one, 10

5α-Androst-3-en-17-ol, 10

5α-Androst-3-en-17-one, 10

5α-Dihydrotestosterone, 5

5-Androstenedione, 5

5F-ADB, 18

5-Methylhexan-2-amine, 16

5-N,6-N-bis(2-fluorophenyl)-[1,2,5] oxadiazolo[3,4-b]pyrazine-5,6-diamine, 11

6-Oxo, 10

7α-Hydroxy-DHEA, 5

7α,11ß-Dimethyl-19-nortestosterone, 5

7α-Methyl-19-nortestosterone, 6

7ß-Hydroxy-DHEA, 5

7-Keto-DHEA, 5

7,8-Benzoflavone, 10

11ß-Methyl-19-nortestosterone, 5

11-Ketoandrostenedione, 5

17α-Methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17ß-ol, 5

17α-Methyl-5α-androst-2-en-17ß-ol, 5

17α-Methyl-5α-androst-3-en-17ß-ol, 5

17α-Methylepithiostanol, 5

17ß-Hydroxy-2α,17α-dimethyl-5α-androstan-3-one, 6

17ß-Hydroxy-5α-androst-1-en-3-one, 5

17ß-Hydroxy-5α-androstan-3-one, 5

17ß-Hydroxy-5ß-androstan-3-one, 5

17ß-hydroxy-17α-methyl-5α-androst-1-en-3-one, 6

17ß-Hydroxy-17α-methylandrosta-1,4-dien-3-one, 6

17ß-Hydroxy-17α-methylestr-4-en-3-one, 6

17ß-Hydroxy-17α-methylestra-4,9-dien-3-one, 6

17ß-Hydroxy-17α-methylestra-4,9,11-trien-3-one, 6

17ß-Hydroxyestr-4,9,11-trien-3-one, 6

17ß-[(Tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane, 6

17-Hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one, 6

19-Norandrostenediol, 5

19-Norandrostenedione, 5

19-Norpregna-4-en-17α-ol, 5

19-Nortestosterone, 6

α-Naphthoflavone, 10

α-Pyrrolidinovalerophenone, 16

ß-Methylphenylethylamine, 16

A

AB-FUBINACA, 18

ACE-031, 11

Acebutolol, 20

Acetazolamide, 12

Activators of the AMP-activated protein kinase (AMPK), 11

Activin A-neutralizing antibodies, 11

Activin receptor IIB competitors, 11

Adrafinil, 15

Adrenaline, 16

Adrenosterone, 5

AICAR, 11

Albumin, 12

Alexamorelin, 8

Alprenolol, 20

Amfepramone, 15

Amfetamine, 15

Amfetaminil, 15

Amiloride, 12

Aminoglutethimide, 10

Amiphenazole, 15

AMP-activated protein kinase (AMPK), 11

Anamorelin, 8

Anastrozole, 10

Andarine, 6

Androst-4-ene-3ß,17ß-diol, 5

Androst-4-ene-3,11,17- trione, 5

Androst-4-ene-3,17-dione, 5

Androst-5-ene-3ß,17ß-diol, 5

Androst-5-ene-3,17-dione, 5

Androsta-1,4,6-triene-3,17-dione, 10

Androsta-1,4-diene-3,17-dione, 5

Androsta-3,5-diene-7,17-dione, 10

Androstanolone, 5

Androstatrienedione, 10

Androstenediol, 5

Androstenedione, 5

Anti-activin receptor IIB antibodies, 11

AOD-9604, 8

Apheresis, 13

Apitegromab, 11

Arformoterol, 9

Arimistane, 10

ARM210, 4

Asialo EPO, 7

Atenolol, 20

B

BAM15, 11

Bazedoxifene, 10

Beclometasone, 19

INDEX

Bendroflumethiazide, 12
Benfluorex, 15
Benzfetamine, 16
Benzylpiperazine, 15
Betamethasone, 19
Betaxolol, 20
Bimagrumab, 11
Bisoprolol, 20
Blood, 13
Blood (autologous), 13
Blood (components), 13
Blood (heterologous), 13
Blood (homologous), 13
Blood manipulation, 13
Blood withdrawal, 13
BMPEA, 16
Bolasterone, 5
Boldenone, 5
Boldione, 5
BPC-157, 4
Brimonidine, 16
Brinzolamide, 12
Bromantan, 15
Budesonide, 19
Bumetanide, 12
Bunolol, 20
Buprenorphine, 17
Bupropion, 16
Buserelin, 8

C

Caffeine, 16
Calusterone, 5
Cannabidiol (CBD), 18
Cannabis, 18
Canrenone, 12
Capromorelin, 8
Carbamylated EPO (CEPO), 7
Carbon monoxide, 13
Carphedon, 15
Carteolol, 20
Carvedilol, 20
Cathine, 12, 16
Cathinone, 16
Celiprolol, 20
Cell (doping), 14
Cell (genetically modified), 14
Cell (normal), 14
Cell (red blood), 13
Cell components (nuclei), 14
Cell components (mitochondria), 14
Cell components (ribosomes), 14
Chlorothiazide, 12
Chlortalidone, 12
Chorionic Gonadotrophin (CG), 8
Ciclesonide, 19
CJC-1293, 8
CJC-1295, 8
Clenbuterol, 6
Clobenzorex, 15
Clomifene, 10
Clonazoline, 16
Clonidine, 16
Clostebol, 5
CNTO-530, 7
Cobalt, 7
Cocaine, 15
Conivaptan, 12
Corticorelin, 8
Corticotrophins, 8
Cortisone, 19
Cropropamide, 15
Crotetamide, 15
Cyclofenil, 10

D

Danazol, 5
Daprodustat, 7
Darbepoetins (dEPO), 7
Deflazacort, 19
Dehydrochlormethyltestosterone, 5
Dehydroepiandrosterone (DHEA), 6
Delta-8-tetrahydrocannabinol (Δ^8-THC), 18
Delta-9-tetrahydrocannabinol (Δ^9-THC), 18
Delta-10-tetrahydrocannabinol (Δ^{10}-THC), 18
Deslorelin, 8
Desmopressin, 12
Desoxymethyltestosterone, 5
Dexamethasone, 19
Dextran, 12
Dextromoramide, 17
Diamorphine, 17
Dimetamfetamine, 16
Dimethandrolone, 5
Dimethylamphetamine, 16
Domagrozumab, 11
Dorzolamide, 12
Drospirenone, 12
Drostanolone, 5

E

Ecstasy, 15
Efaproxiral (RSR13), 13
Elacestrant, 10
Enobosarm, 6
Ephedrine, 12, 16
Epiandrosterone, 5
Epi-dihydrotestosterone, 5
Epinephrine, 16
Epistane, 5
Epitestosterone, 5
Eplerenone, 12
EPO-based constructs, 7
EPO-Fc, 7
EPO-mimetic agents, 7
Erythropoietin receptor agonists, 7
Erythropoietins (EPO), 7
Esmolol, 20
Esters of anabolic androgenic steroids, 6
Estr-4-ene-3,17-diol, 5
Estr-4-ene-3,17-dione, 5
Etacrynic acid, 12
Etamivan, 16
Ethylestrenol, 5
Ethylphenidate, 16
Etilamfetamine, 16
Etilefrine, 16
Examorelin, 8
Exemestane, 10

F

Famprofazone, 16
Felypressin, 12
Fenbutrazate, 16
Fencamfamin, 16
Fencamine, 15
Fenetylline, 15
Fenfluramine, 15
Fenoterol, 9
Fenoxazoline, 16
Fenproporex, 15

INDEX

Fentanyl, 17
Fibroblast growth factors (FGFs), 8
Finerenone, 12
Fladrafinil 15
Flmodafinil 15
Flunisolide, 19
Fluocortolone, 19
Fluorenol, 15
Fluoxymesterone, 5
Fluticasone, 19
Follistatin, 11
Fonturacetam, 15
Formebolone, 5
Formestane, 10
Formoterol, 9, 12
Fulvestrant, 10
Furazabol, 5
Furfenorex, 15
Furosemide, 12

G

GATA inhibitors, 7
Gene doping, 14
Gene editing, 14
Gene silencing, 14
Gene transfer, 14
Gestrinone, 6
Ghrelin, 8
GH-releasing peptides (GHRPs), 8
Gonadorelin, 8
Gonadotrophin-releasing hormone (GnRH), 8
Goserelin, 8
Growth hormone (GH), 8
Growth hormone secretagogues (GHS), 8
Guanfacine, 16
GW1516, 11
GW501516, 11

H

Haemoglobin (products), 13
Haemoglobin (based blood substitutes), 13
Haemoglobin (microencapsulated products), 13
Hashish, 18
Hepatocyte growth factor (HGF), 8
Heptaminol, 16
Heroin, 17
Hexahydrocannabinols (HHC), 18
Hexarelin, 8
hGH 176-191, 8
Higenamine, 9
Histrelin, 8
Hydrafinil, 15
Hydrochlorothiazide, 12
Hydrocortisone, 19
Hydromorphone, 17
Hydroxyamfetamine, 16
Hydroxyethyl starch, 12
Hypoxia-inducible factor (HIF) activating agents, 7

I

Ibutamoren, 8
Imidazoline, 16
Imlunestrant, 10
Indacaterol, 9
Indanazoline, 16
Indapamide, 12
Infusions, 13
Injections (>100 mL), 13
Innate repair receptor agonists, 7
Insulin-like growth factor-1 (IGF-1), 8
Insulin-mimetics, 11
Insulins, 11
Intravenous infusions/injections, 13
IOX2, 7
Ipamorelin, 8
Isometheptene, 16

K

K-11706, 7
Kisspeptin, 8

L

Labetalol, 20
Landogrozumab, 11
Lenomorelin, 8
Letrozole, 10
Leuprorelin, 8
Levmetamfetamine, 16
Levosalbutamol, 9
LGD-4033, 6
Ligandrol, 6
Lisdexamfetamine, 15
Lonapegsomatropin, 8
Luspatercept, 7
Luteinizing hormone (LH), 8

M

Macimorelin, 8
Mannitol, 12
Marijuana, 18
Mecasermin, 8
Mechano growth factors (MGFs), 8
Meclofenoxate, 16
Mefenorex, 15
Meldonium, 11
MENT, 6
Mephedrone, 16
Mephentermine, 15
Mesocarb, 15
Mestanolone, 6
Mesterolone, 6
Metamfetamine(*d*-), 15
Metandienone, 6
Metenolone, 6
Methadone, 17
Methandriol, 6
Methasterone, 6
Methedrone, 16
Methoxy polyethylene glycol-epoetin beta (CERA), 7
Methyl-1-testosterone, 6
Methylclostebol, 6
Methyldienolone, 6
Methylenedioxyamphetamine, 16
Methylenedioxymethamphetamine, 16
Methylephedrine, 12, 16
Methylhexaneamine, 16
Methylnaphtidate, 16
Methylnortestosterone, 6
Methylphenidate, 16
Methylprednisolone, 19
Methylsynephrine, 16
Methyltestosterone, 6
Methyltrienolone, 6
Metipranolol, 20
Metolazone, 12
Metoprolol, 20
Metribolone, 6
Mibolerone, 6
Midodrine, 16
Mitochondria, 14
Mitochondrial open reading frame of the 12S rRNA-c, 11

INDEX

MK-677, 8
Modafinil, 15
Molidustat, 7
Mometasone, 19
Morphine, 17
MOTS-c, 11
Mozavaptan, 12
Myostatin inhibitors, 11
Myostatin precursor-neutralizing antibodies, 11
Myostatin propeptide, 11
Myostatin-binding proteins, 11
Myostatin-neutralizing antibodies, 11

N

Nadolol, 20
Nafarelin, 8
Nandrolone, 6
Naphazoline, 16
Nebivolol, 20
Nicomorphine, 17
Nicotine, 16
Nikethamide, 16
Norboletone, 6
Norclostebol, 6
Norethandrolone, 6
Norfenefrine, 16
Norfenfluramine, 15
Nuclei/nucleus, 14
Nucleic acids, 14
Nucleic acid analogues, 14

O

Octodrine, 16
Octopamine, 16
Olodaterol, 9
Organelles (e.g. nuclei, mitochondria, ribosomes), 14
Osilodrostat, 6
Ospemifene, 10
Ostarine, 6
Oxabolone, 6
Oxandrolone, 6
Oxilofrine, 16
Oxprenolol, 20
Oxycodone, 17
Oxymesterone, 6
Oxymetazoline, 16
Oxymetholone, 6
Oxymorphone, 17

P

Pamabrom, 12
Parahydroxyamphetamine, 16
Peginesatide, 7
Pegmolesatide, 7
Pemoline, 16
Pentazocine, 17
Pentetrazol, 16
Perfluorochemicals, 13
Peroxisome proliferator activated receptor delta agonists, 11
Pethidine, 17
Phendimetrazine, 15
Phenethylamine, 16
Phenmetrazine, 16
Phenpromethamine, 16
Phentermine, 15
Phenylephrine, 16
Phenylpropanolamine, 16
Pindolol, 20
Pipradrol, 16
Plasma expanders, 12
Platelet-derived growth factor (PDGF), 8
p-methylamfetamine, 15
Pralmorelin, 8
Prasterone, 6
Prednisolone, 19
Prednisone, 19
Prenylamine, 15
Probenecid, 12
Procaterol, 9
Prolintane, 15
Propranolol, 20
Propylhexedrine, 16
Prostanozol, 6
Proteases, 13
Pseudoephedrine, 12, 16

Q

Quinbolone, 6

R

RAD140, 6
Ractopamine, 6
Raloxifene, 10
Reldesemtiv, 4
Reproterol, 9
Rev-erbα agonists, 11
Roxadustat, 7
Ryanodine receptor-1-calstabin complex stabilizers, 4
Re-breathing systems or equipment to deliver carbon monoxide, 13
Ribosomes, 14

S

S-107, 4
S-23, 6
S48168, 4
S519, 11
S597, 11
Salbutamol, 9, 12
Salmeterol, 9
Seladelpar, 11
Selective androgen receptor modulators (SARMs), 6
Selective Estrogen Receptor Modulators (SERMs), 10
Selective Estrogen Receptor Degraders (SERDs), 10
Selegiline, 16
Sermorelin, 8
Sibutramine, 16
SLU-PP-332, 11
SLU-PP-915, 11
Solriamfetol, 16
Somapacitan, 8
Somatrogon, 8
Sotalol, 20
Sotatercept, 7
Spironolactone, 12
SR9009, 11
SR9011, 11
Stamulumab, 11
Stanozolol, 6
Stenbolone, 6
Strychnine, 16
Synephrine, 16

T

Tabimorelin, 8
Tamoxifen, 10
Tampering, 13
TB-500, 8
Tenamfetamine, 16
Terbutaline, 9
Tesamorelin, 8

INDEX

Tesofensine, 16
Testolactone, 10
Testosterone, 6
Testosterone-stimulating peptides 8
Tetracosactide, 8
Tetrahydrocannabinols, 18
Tetrahydrogestrinone, 6
Tetryzoline, 16
Thiazides, 12
Thymosin-ß4, 8
Tibolone, 6
Timolol, 20
Tirasemtiv, 4
Tolvaptan, 12
Torasemide, 12
Toremifene, 10
Tramadol, 17
Tramazoline, 16
Transforming growth factor beta (TGF-ß) signalling inhibitors, 7
Trenbolone, 6
Trestolone, 6
Tretoquinol, 9
Triamcinolone acetonide, 19
Triamterene, 12
Trimetazidine, 11
Trimetoquinol, 9
Triptorelin, 8
Troponin activators, 4
Tuaminoheptane, 16
Tulobuterol, 9

V

Vadadustat (AKB-6548), 7
Vaptans, 12
Vascular endothelial growth factor (VEGF), 8
Vilanterol, 9
Voxelotor, 13

X

Xenon, 7
Xipamide, 12
Xylometazoline, 16

Y

YK-11, 6

Z

Zeranol, 6
Zilpaterol, 6

wada

www.wada-ama.org



www.wada-ama.org